{
  "docId": "019de071-b48b-74ad-8fcb-69ba4c0494fb",
  "docSlug": "4047dd7a7e0f28ca31128b58ef648c55",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 39,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Includes a footnote defining STRIDE regimen.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b48b-74ad-8fcb-69ba4c0494fb/19",
  "deckHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb",
  "deckJsonHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb.json",
  "deckAnchorHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.07,
        "x": 0.24,
        "y": 0.62
      },
      "kind": "callout",
      "text": "US FDA ODD received",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e20b085-cf5f-40da-9f65-6566265dc79f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.07,
        "x": 0.56,
        "y": 0.62
      },
      "kind": "callout",
      "text": "US FDA ODD received",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfe65a27-ed11-44a3-937f-348621483e41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 1,
        "w": 0.35,
        "x": 0.65,
        "y": 0
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "580e72af-af5c-4e88-b84a-e931701f39c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.35,
        "y": 0.23
      },
      "kind": "list",
      "text": "Imfinzi TOPAZ-1 + chemo in 1st-line biliary tract cancer: Met primary endpoint of improved overall survival; Improvement in progression-free survival and overall response rate; Strong safety profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94a4a15c-bf46-42b2-a015-b94e13e5c345",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.03,
        "y": 0.23
      },
      "kind": "list",
      "text": "Imfinzi + treme HIMALAYA 1st-line liver cancer: Combination met primary endpoint of improved overall survival versus sorafenib; Positive data for STRIDE regimen; Favourable safety profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5151e28-5811-426c-a8a1-4419906c0777",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.03,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "New prospects for immuno-oncology franchise in gastrointestinal cancers",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e4af6c4-abe7-40e5-aca6-f22388247210",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.03,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "STRIDE = Single Tremelimumab Regular Interval Durvalumab.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2240ceb-c87f-4065-b0a5-76da7a671cdb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Positive data in liver cancer and biliary tract cancer",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f31ca2bf-e154-4b95-a5b7-ce25b24ccb71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oncology: R&D pipeline highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f98381e-d66c-477d-93d9-4804122287be",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 14,
      "beatId": "c438a04c-1fcd-49aa-a3b3-c1d3c21b10b6",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document showcases the company's strong presence in Oncology, with key highlights and positive data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 14,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f40460eb-a408-4c4b-b4fa-e51e50631502",
      "evidence": "The document uses the golden circle to present the company's Oncology pipeline and highlight its potential for growth.",
      "position": 1,
      "objective": "To showcase the company's strong presence in Oncology and demonstrate its potential for growth.",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}